SK Bioscience stock faces a 161 participant mRNA checkpoint

SK Bioscience stock faces a 161 participant mRNA checkpoint as the company prepares to assess GBP560, its Japanese encephalitis vaccine candidate. EDAILY reported on September 25, 2026, that the global Phase 1 trial had finished and that results are expected by the end of 2026.

GBP560 reaches its next test

The trial enrolled 161 participants, compared with 402 participants originally planned for the combined Phase 1 and Phase 2 program, according to EDAILY. The article said the treatment design remained unchanged, with six groups testing two candidate compounds at three dose levels.

The next decision is conditional on the Phase 1 data. EDAILY reported that SK Bioscience plans to decide on Phase 2 after reviewing the results, making the year-end update an important development checkpoint for the pipeline.

Revenue improves sequentially, losses persist

SK Bioscience generated KRW 155.7 billion in revenue during the second quarter of 2026, down 3.80 percent from the year-earlier period, while operating loss reached KRW 15.7 billion. The figures were reported by ATS View from the company's quarterly reporting data.

The quarterly loss nevertheless narrowed from KRW 44.5 billion in the first quarter of 2026 to KRW 15.7 billion in the second quarter, while revenue declined from KRW 168.6 billion to KRW 155.7 billion. That combination points to a sequential improvement in operating pressure, but the negative result keeps execution central to the investment case.

KOSPI valuation keeps the trial in view

SK Bioscience had a market capitalization of KRW 2.8 trillion on September 29, 2026. Its primary-exchange quote was last at KRW 35,900.00 on the KOSPI on September 29, 2026 at 3:30 p.m. KST, with a 52-week range of KRW 31,800.00 to KRW 61,300.00.